Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

ITIH4 serum concentration increases during acute-phase processes in human patients and is up-regulated by interleukin-6 in hepatocarcinoma HepG2 cells.

Authors: Pineiro, M  Alava, MA  Gonzalez-Ramon, N  Osada, J  Lasierra, P  Larrad, L  Pineiro, A  Lampreave, F 
Citation: Pineiro M, etal., Biochem Biophys Res Commun. 1999 Sep 16;263(1):224-9.
Pubmed: (View Article at PubMed) PMID:10486281
DOI: Full-text: DOI:10.1006/bbrc.1999.1349

The serum concentration of the inter-alpha trypsin inhibitor heavy chain 4 protein (ITIH4) increases (from 1.4-3 times) in male patients suffering of different acute-phase processes (myocardial infarction, unstable angina or programmed surgery). The concentration of C-reactive protein (CRP) in these samples ranged from 15 microg/ml to 133 microg/ml. Using the hepatocarcinoma HepG2 cell line we have observed up-regulation of ITIH4 mRNA expression upon dose-response treatments with interleukin-6 (IL-6). This effect correlates with the increase of radiolabeled ITIH4 in the cellular media of (35)S-labeled HepG2 cells treated with the cytokine. A similar effect was observed for haptoglobin mRNA, used as a control for acute-phase protein expression. IL-1beta, although up-regulating the expression of alpha(1)-acid glycoprotein in these cells, did not induce any effect in the expression of ITIH4. No changes were observed after TNF-alpha treatments. The results presented here indicate that ITIH4 is a type II acute-phase protein in humans.


Disease Annotations
Objects Annotated

Additional Information

RGD Object Information
RGD ID: 1582334
Created: 2006-11-06
Species: All species
Last Modified: 2006-11-06
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.